Why the study?
Left cardiac sympathetic denervation is indicated for refractory long QT syndrome in Europe and the United States, but is rarely performed in Japan because it is not covered by national health insurance.
Thoracoscopic left cardiac sympathetic denervation with careful perioperative anesthetic management can safely suppress life-threatening arrhythmias in patients with refractory long QT syndrome and severe heart failure.
Should not yet change practice; leaves open the role of thoracoscopic LCSD in refractory LQTS with severe HF.
BACKGROUND: Long QT syndrome (LQTS) refractory to standard treatments, including β-blockers and implantable cardioverter-defibrillators (ICDs), has been indicated for left cardiac sympathetic denervation (LCSD) in Europe and the United States. However, the clinical implementation of LCSD remains rarely performed in Japan as it is not covered by national health insurance. CASE PRESENTATION: A 49-year-old woman with LQTS experienced frequent ICD activations, and β-blocker up-titration was limited due to severe heart failure. As a stellate ganglion block transiently shortened QT interval, LCSD was considered to prevent life-threatening arrhythmic events. Total intravenous anesthesia combined with a left thoracic paravertebral block was used to attenuate sympathetic nervous activation. Thoracoscopic LCSD was performed without arrhythmia or hemodynamic instability. The patient remained stable postoperatively, with no further ICD activations. CONCLUSION: This case demonstrates the safe perioperative management of LCSD for drug-refractory LQTS by incorporating strategies to minimize QT prolongation and suppress malignant arrhythmias.
No takes yet. Share an insight, caveat, or question.
Nitta et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: